ScripFollowing the failure of its antibiotic ridinilazole in Clostridium difficile infection in December 2021, Summit Therapeutics plc executed a pivot from anti-infectives to oncology a year later whe
HBW InsightAfter abuse-deterrent opioid formulations reached a dead-end, the US Food and Drug Administration again is seeing growth in applications for new products that address the opioid crisis. In addition to
Pink SheetAfter abuse-deterrent opioid formulations reached a dead-end, the US FDA is again seeing growth in applications for new products that address the opioid crisis, led by not one but two applications for
ScripAcrivon Therapeutics, Inc. brought its initial public offering to the US market a week later than originally planned and at different terms than it proposed a week earlier, but the cancer drug develo